Eli Lilly, an American pharmaceutical company and Santec Holdings, a global photonics company and a manufacturer, led a JPY1.5bn Series C funding round in PRISM BioLab, a discovery and development biotechnology company. We feel confident that PRISM BioLab's promising and unique approach to drug discovery will lead to breakthrough therapeutic drugs that were previously unattainable. Santec is engaged in the development of medical imaging devices and early diagnosis utilizing Photonics. We believe that the advancement of these technologies, in conjunction with innovative drug discovery techniques, is pivotal for the comprehensive improvement of patients' Quality of Life. Changho Chong, Santec Holdings Executive Vice President & CTO.